SMARCA4 and non-small cell lung carcinoma: CRISPR was used to knockout (KO) BRG1 in non-malignant, pre-malignant (cigarette smoke-transformed), and malignant (NSCLC) human lung epithelium-derived cell lines, and the effects on their early initiation, progression, and therapeutic vulnerability were investigated in vitro and in vivo.